In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Adverum Biotechnologies (NASDAQ: ADVM). The company’s shares opened today at $5.75.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.4% and a 51.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Vertex Pharmaceuticals.
Adverum Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $11.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.59 and a one-year low of $2.40. Currently, Adverum Biotechnologies has an average volume of 1.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
